文献速递白血病

口服生物可利用的GSPT1/2降解剂SJ6986在急性淋巴细胞白血病中展现体内疗效

The orally bioavailable GSPT1/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2023-01-01

研究开发了新型cereblon调节剂SJ6986,可强效选择性降解GSPT1和GSPT2。体外实验中SJ6986对白血病细胞系的细胞毒性与CC-90009相似,诱导凋亡并干扰细胞周期;体内实验中SJ6986比CC-90009更有效抑制白血病细胞生长,部分归因于有利的药代动力学特性,且未显著损害人CD34+细胞体外分化。全基因组CRISPR/Cas9筛选证实CRL4CRBN复合体组分介导SJ6986作用。SJ6986是强效、选择性、口服生物可利用的GSPT1/2降解剂,具有广泛抗白血病活性并有临床开发潜力。

要点

  • SJ6986强效选择性降解GSPT1和GSPT2,对儿童癌症细胞系有细胞毒活性。
  • 体外SJ6986与CC-90009细胞毒性相似,诱导凋亡并干扰细胞周期。
  • 体内SJ6986比CC-90009更有效抑制白血病细胞生长,部分归因于有利药代动力学。

核心结论

  • SJ6986是强效、选择性、口服生物可利用的GSPT1/2降解剂,具有广泛抗白血病活性并有临床开发潜力。

研究设计与样本

  • 研究对一组急性淋巴细胞白血病细胞系和异种移植模型进行SJ6986的体外和体内活性检测。

主要发现

  • SJ6986在体外一组白血病细胞系中展现与CC-90009相似的细胞毒性,诱导凋亡并干扰细胞周期进程。
  • SJ6986在体内抑制白血病细胞生长方面比CC-90009更有效,部分归因于有利的药代动力学特性。
  • SJ6986未显著损害人CD34+细胞的体外分化。
  • 全基因组CRISPR/Cas9筛选证实CRL4CRBN复合体组分、相关适配器、调节因子和效应器介导SJ6986作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Advancing cure rates for high-risk acute lymphoblastic leukemia (ALL) has been limited by the lack of agents that effectively kill leukemic cells, sparing normal hematopoietic tissue. Molecular glues direct the ubiquitin ligase cellular machinery to target neosubstrates for protein degradation. We developed a novel cereblon modulator, SJ6986, that exhibits potent and selective degradation of GSPT1 and GSPT2 and cytotoxic activity against childhood cancer cell lines. Here, we report in vitro and in vivo testing of the activity of this agent in a panel of ALL cell lines and xenografts. SJ6986 exhibited similar cytotoxicity to the previously described GSPT1 degrader CC-90009 in a panel of leukemia cell lines in vitro, resulting in apoptosis and perturbation of cell cycle progression. SJ6986 was more effective than CC-90009 in suppressing leukemic cell growth in vivo, partly attributable to favorable pharmacokinetic properties, and did not significantly impair differentiation of human CD34+ cells ex vivo. Genome-wide CRISPR/Cas9 screening of ALL cell lines treated with SJ6986 confirmed that components of the CRL4CRBN complex, associated adaptors, regulators, and effectors were integral in mediating the action of SJ6986. SJ6986 is a potent, selective, orally bioavailable GSPT1/2 degrader that shows broad antileukemic activity and has potential for clinical development.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Chang Y, Keramatnia F, Ghate PS, et al. The orally bioavailable GSPT1/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemia. Blood. 2023. PMID: 37172201. doi:10.1182/blood.2022017813

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。